Mental health · Maitland, FL
Mental health studies in Maitland, FL
19 recruiting studies have a site in Maitland.
19 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Definium Therapeutics US, Inc.
- Location
- Maitland, FL + 22 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Maitland, FL + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Cybin IRL Limited
- Location
- Maitland, FL + 27 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Maitland, FL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Maitland, FL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- Maitland, FL + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- Maitland, FL + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Maitland, FL + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Maitland, FL + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Maitland, FL + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Maitland, FL + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Maitland, FL + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals, Inc.
- Location
- Maitland, FL + 25 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Maitland, FL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Maitland, FL + 7 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Maitland, FL + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Maitland, FL + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Maitland, FL + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Maitland, FL + 12 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.